PALM BEACH, Fla., Oct. 21, 2020 /PRNewswire/ — Cancer immunotherapy has emerged as a new avenue for revenue generation for pharmaceutical companies. Adverse effects, such as recurrence of cancer and Key players in the aerosol actuators market include Lindal Group, Aptar Group, Coster Group, Mitani Valve Co. Ltd., Summit Packaging Systems, Presspart Manufacturing Ltd., Precision Valve Corporation, E C Pack Industrial Ltd., Ultramotive Corporation, and Newman-Green Inc., among others.New York, Oct URBANA — The coronavirus tests being done at the state’s drive-thru site at Market Place Mall are no longer going to Carle’s in-house lab for results. This 4 bedroom, 3 bathroom Jonesboro home is in walking distance of Lake Jodeco. Oman moved ahead with its borrowing plan days after S&P cut its debt rating to B+, four rungs below investment grade. Ethereum has bounced off the 50 SMA on the daily chart
PALM BEACH, Fla., Oct. 21, 2020 /PRNewswire/ — Cancer immunotherapy has emerged as a new avenue for revenue generation for pharmaceutical companies. Adverse effects, such as recurrence of cancer and organ failure, associated with conventional chemotherapies and rising demand for technologically advanced healthcare solutions are boosting the demand for immunotherapies. Moreover, introduction of newer drug classes, such as target receptors for multiple myeloma and checkpoint inhibitors, is poised to make way for advanced therapeutics in the market. Monoclonal antibodies are the most widely used immunotherapeutic drugs globally. Development of monoclonal antibodies as effective immunotherapeutic options are resulting in discovery of new therapeutic options for cancer treatment. A recent industry report from MarketsAndMarkets projected that the global immunotherapy drugs market is projected to reach USD 274.6 billion by 2025 from USD 163.0 billion in 2020, at a CAGR of 11.0 % during the forecast period. The growth of this market is majorly attributed to the rising prevalence of target diseases, increasing demand for monoclonal antibodies and biosimilars, increasing adoption of immunotherapy drugs over conventional treatments, and a favorable approval scenario. However, timeline issues, side-effects, and manufacturing complexities and a high attrition rate in the product development cycle are expected to challenge market growth. Active biotech and pharma companies in the markets this week include Actinium Pharmaceuticals, Inc. (NYSE: ATNM), AstraZeneca PLC (NASDAQ: AZN), Bristol Myers Squibb (NYSE: BMY), Northwest Biotherapeutics (OTCQB: NWBO), Merck (NYSE: MRK).
The report said that: “Based on type, the immunotherapy drugs market is segmented into monoclonal antibodies, checkpoint inhibitors, interferons & interleukins, and other immunotherapies. The monoclonal antibodies segment accounted for the largest share of the global immunotherapy drugs market in 2019. This large share can be attributed to their high specificity and fewer side-effects, increasing focus on personalized medicines, initiatives by industry players, and the rising target disease incidence and patient pool… On the basis of therapeutic area, this market is segmented into cancer, autoimmune & inflammatory diseases, infectious diseases, and other therapeutic areas. Cancer accounted for the largest share of the global immunotherapy drugs market, by therapeutic area, in 2019. The large share of this segment can be attributed to the growing prevalence of cancer, rising research activity in this area, and reimbursement coverage for immunotherapies for oncology.”
Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) BREAKING NEWS: Actinium Pharmaceuticals, Inc. Awarded Grant by National Institutes of Health to Study Novel Iomab-ACT Targeted Conditioning with a CD19 CAR T-Cell Therapy – Actinium Pharmaceuticals, Inc. (“Actinium” or the “Company”) today announced that the National Institutes of Health has awarded Actinium a Small Business Technology Transfer grant to support a clinical collaboration with Memorial Sloan Kettering Cancer Center (“MSK”) to study Iomab-ACT, Actinium’s CD45-targeting Antibody Radio-Conjugate, for targeted conditioning to achieve lymphodepletion prior to administration of a CD19-targeted CAR T-cell therapy developed at MSK. The CD19 CAR-T has been previously studied by MSK in a Phase 2 trial with chemotherapy conditioning in patients with relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) or diffuse large B-cell lymphoma (DLBCL). MSK will lead this first of its kind study to utilize targeted radiopharmaceutical ARC-based lymphodepletion to replace chemotherapy-based conditioning prior to CAR T-cell therapy. The study will assess the feasibility of using Iomab-ACT targeted lymphodepletion prior to MSK’s 19-28z CAR-T and assess safety and efficacy outcomes relative to results with MSK’s CAR-T 19-28z in patients who had received chemotherapy-based lymphodepletion prior to CAR-T administration.
Results published in the New England Journal of Medicine with MSK’s 19-28z CD19 CAR-T in 53 patients with R/R B-ALL reported complete remissions in 83% (44/53) of patients. Median event-free survival (EFS) was 6.1 months and median overall survival (OS) was 12.9 months at a median follow up period of 29 months (range 1 – 65 months) for all patients. Patients with low disease burden, defined as less than 5% blasts in the bone marrow, had markedly enhanced outcomes with increased median EFS of 10.6 months and median OS of 20.1 months. There was a 26% (14/53) rate of Grade 3 of greater cytokine release syndrome (CRS), with 1 patient death as a result, and 42% of patients experienced Grade 3-4 immune effector cell-associated neurotoxicity syndrome (ICANS). In addition to improved duration of response and survival, patients with low disease burden prior to receiving CAR T-cell therapy had lower rates of CRS and neurotoxicity.
“We are excited to be collaborating with MSK on this trial as they are a leader in the field of cellular therapies. We selected MSK’s 19-28z CAR T-cell therapy for this NIH grant funded collaboration because it has produced high response rates in patients with relapsed or refractory B-ALL who have previously undergone several lines of standard therapy. However, toxicities such as cytokine release syndrome and neurologic toxicity, as well as durability of response, remain a challenge as is the case with many other CAR T-cell therapies” commented Dr. Mark Berger, Actinium’s Chief Medical Officer. “Iomab-ACT enables the delivery of targeted radiation that selectively and specifically targets immune cells, including those implicated in the CAR-T-associated toxicities of cytokine release syndrome and neurotoxicity. We are hopeful that this study will demonstrate improvements in safety and outcomes with MSK’s CAR 19-28z as a result of Iomab-ACT targeted lymphodepletion and that this will allow clinicians to make important improvements in patients’ ability to receive CAR T-cell therapies.”
CAR-T is a type of cellular therapy in which a patient’s own (autologous) T-cells are genetically engineered outside of the body to target the patient’s cancer cells and which are then reinfused back into the patient to seek out and kill cancer cells. Currently there are 2 approved CD19 targeted CAR-T therapies, which both require chemotherapy-based conditioning to deplete the patient’s lymphocytes, known as lymphodepletion, and many other CAR-T constructs in development that also use chemotherapy conditioning for lymphodepletion.
Iomab-ACT targets cells that express CD45, an antigen found on immune cells such as lymphocytes and macrophages as well as leukemia and lymphoma cancer cells and delivers the radioisotope warhead iodine-131 to achieve cell depletion. Iomab-ACT is intended to deplete CD45+ immune cells such as macrophages that are implicated in CAR-T related toxicities and may also have an anti-tumor effect on chemo-refractory cancers. Iomab-ACT is a low dose extension of Actinium’s lead program, Iomab-B, which is being studied in a pivotal Phase 3 trial for targeted conditioning prior to a bone marrow transplant. Preclinical data supporting Iomab-ACT’s application in targeted lymphodepletion prior to ACT such as CAR-T was recently published in the journal Oncotarget (https://www.oncotarget.com/archive/v11/i39/). In addition, clinical data with trace doses of Iomab-B has shown transient, reversible lymphodepletion in patients and drug clearance pharmacokinetics that fit within the vein to vein time of CAR-T manufacturing and administration.
Sandesh Seth, Actinium’s Chairman and CEO, said, “This clinical trial collaboration with MSK is a strong step forward for Actinium and our targeted conditioning program. The 19-28z CAR-T has already produced promising data and we look forward to working with MSK to explore Iomab-ACT’s potential to reduce toxicities and improve patient outcomes. As we advance towards the SIERRA interim analysis in the fourth quarter, we are focused on the continued expansion of our ARC-based targeted conditioning program for bone marrow transplant and cell and gene therapies with the goal of providing targeted conditioning regimens that are less toxic and more effective than current chemotherapy-based conditioning. With these therapies being administered in a select number of concentrated centers, we see a large and growing market opportunity where our ARC-based targeted conditioning can improve outcomes and increase access to these important curative treatment options.” Read this full release and more news for ATNM at: https://www.financialnewsmedia.com/news-atnm/ Other recent developments in the biotech industry include:AstraZeneca PLC (NASDAQ: AZN) AstraZeneca’s TAGRISSO® (osimertinib) recently announced it has received acceptance for its supplemental New Drug Application (sNDA) and has also been granted Priority Review in the US for the adjuvant treatment of patients with early-stage (IB, II and IIIA) epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) after complete tumor resection with curative intent.
While up to 30% of all patients with NSCLC may be diagnosed early enough to have potentially curative surgery, disease recurrence is still common in early-stage disease and nearly half of patients diagnosed in Stage IB, and over three quarters of patients diagnosed in Stage IIIA, experience recurrence within five years.
Bristol Myers Squibb (NYSE:BMY) recently announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of Opdivo (nivolumab) for the treatment of adults with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC) after prior fluoropyrimidine- and platinum-based combination chemotherapy. The European Commission (EC), which is authorized to approve medicines for the European Union (EU), will now review the CHMP recommendation.
“This positive CHMP opinion underscores the potential of Opdivo in the EU treatment landscape for esophageal squamous cell carcinoma, with the ATTRACTION-3 trial showing clinically meaningful survival coupled with a favorable safety profile,” said Ian M. Waxman, M.D., development lead, gastrointestinal cancers, Bristol Myers Squibb. “We look forward to the EC’s final decision, which could mark the first time an immunotherapy is approved for any upper gastrointestinal cancer in the EU. We remain committed to continuing to explore the potential benefits of Opdivo in earlier settings of esophageal cancer.”
Merck (NYSE: MRK), known as MSD outside the United States and Canada, recently announced findings from two additional Phase 3 studies evaluating the safety, tolerability and immunogenicity of V114, the company’s investigational 15-valent pneumococcal conjugate vaccine. In the PNEU-PATH (V114-016) study, healthy adults 50 years of age or older received V114 or PCV13 followed by PNEUMOVAX® 23 one year later. Immune responses following vaccination with PNEUMOVAX 23 (month 13) were comparable in both vaccination groups for the 15 serotypes in V114. Results also showed that at 30 days post vaccination with either V114 or PCV13 (day 30), immune responses were comparable for both groups across the 13 serotypes shared by the conjugate vaccines and higher in the V114 group for serotypes 22F and 33F, the two serotypes not included in PCV13. In PNEU-DAY (V114-017), a Phase 3 study in immunocompetent adults 18 to 49 years of age with underlying medical conditions associated with increased risk for pneumococcal disease, V114 generated immune responses generally comparable to PCV13 for the 13 shared serotypes and higher immune responses for serotypes 22F and 33F at 30 days post-vaccination. Results from both studies are based on opsonophagocytic activity (OPA) responses – a measure of vaccine-induced functional antibodies. V114 was generally well tolerated in both studies, with a safety profile consistent with that observed for V114 in previously reported studies.
Northwest Biotherapeutics (OTCQB: NWBO), a biotechnology company developing DCVax®personalized immune therapies for solid tumor cancers, recently announced that the database for the Phase III trial of DCVax®-L for Gliobastoma has been locked. With the database now locked, the independent service firms managing the Clinical Trial are arranging for the independent statisticians to have access to the unblinded raw data from the Trial. Neither the Company nor any party other than the independent statisticians will have access to any unblinded data at this stage.
The statisticians will proceed as quickly as possible with analyses of the raw data and prepare summaries of the Trial results for review by the Company, the Principal Investigator, the Steering Committee of the Trial, the Scientific Advisory Board, and a panel of independent brain cancer experts, who will analyze the data with the statisticians in preparation for public announcement and scientific publication.
DISCLAIMER: FN Media Group LLC (FNM), which owns and operates FinancialNewsMedia.com and MarketNewsUpdates.com, is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated in any manner with any company mentioned herein. FNM and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNM’s market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release. FNM is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. For current services performed FNM has been compensated forty five hundred dollars for news coverage of the current press releases issued by Actinium Pharmaceuticals, Inc. by a non-affiliated third party. FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNM undertakes no obligation to update such statements.
Media Contact email: email@example.com – +1(561)325-8757
Aerosol Actuators Market To Reach USD 1,587.5 Million By 2027 | Reports and Data
Key players in the aerosol actuators market include Lindal Group, Aptar Group, Coster Group, Mitani Valve Co. Ltd., Summit Packaging Systems, Presspart Manufacturing Ltd., Precision Valve Corporation, E C Pack Industrial Ltd., Ultramotive Corporation, and Newman-Green Inc., among others.
New York, Oct. 21, 2020 (GLOBE NEWSWIRE) — Increasing aerosol related household & personal care products use due to the ease of product usage coupled with reduced human interaction during product dispensing is projected to fuel demand for Aerosol Actuators.
The global Aerosol Actuators market is forecasted to reach USD 1,587.5 Million by 2027, according to a new report by Reports and Data. The market is distinguished by the involvement of various companies engaged in the manufacturing of high volume actuators. The growing prevalence of respiratory diseases, like asthma, especially in developed countries, is projected to drive the market for aerosol inhalers worldwide. The rising usage of relief sprays by physiotherapists and players in sports for on-field injuries treatment is anticipated to drive the aerosol demand in healthcare applications, thus driving the market growth of actuators.
The increased usage of personal grooming products due to growing inclination towards personal care and appearance is a significant factor in propelling market growth. Increasing aerosol actuators’ usage in nasal sprays, therapeutic lotion dispensers, and other easy-to-use prescription items is projected to fuel the demand for aerosol actuators in the upcoming years. Technological advancements in the design and development of actuators for improving product aesthetics and ease of usage have resulted in increased product demand, e.g., the factories in China import low-cost raw materials from the industries in the market.
Get FREE Sample Copy with TOC of the Report to understand the structure of the complete report@ https://www.reportsanddata.com/sample-enquiry-form/3643
Key industry players are engaged in producing personalized and regular actuators supplied via a dedicated supply chain connectivity leading aerosol producers and fillers. The majority of the company’s large-scale production runs the industry by direct partnerships with leading aerosol manufacturers. With the growing demand for respiratory devices and asthma inhalers, the industry has experienced strong demand for dose actuators in the healthcare sector over the last few years.
The COVID-19 impact:
As the COVID-19 crisis is rising, producers are rapidly changing their activities and purchasing strategies to meet the demands of a pandemic that has developed the need for Aerosol Actuators based on the market. A series of unprecedented sitiations will arise over a few months as producers and their vendors adapt to changing customer demands. Various regions are vulnerable to export-dependent economies, in this unfortunate global situation. The impact of this pandemic will reshape the global Aerosol Actuators markets when certain manufacturers either close down or decrease their production due to a lack of downstream demand. Some nations have their production suspended by their respective governments as a precautionary measure to combat the spread of the virus. Market dynamics in Asia Pacific regions have become very unpredictable, weakening regularly and finding it impossible to stable themselves.
Further key findings from the report suggest
Based on Product, Dosage Actuators generated a revenue of USD 328.4 Million in 2019. It is projected to rise with a CAGR of 5.2% in the forecast period, owing to growing usage for dosage aerosol actuators products in respiratory devices.
The Steel-Tinplate Actuators expected to grow with a CAGR of 4.6% in the forecasted period, owing to its wide variety of applications in household products that place a greater emphasis on the pressure of the containers.
The personal care sector is the major contributor to the Aerosol Actuators market. The personal care sector of the European region is the major shareholder of the market and held around 36.0% of the market in the year 2019, owing to the increasing usage for spray-based personal care items comprising hairsprays and shaving creams.
Europe dominated the market for Aerosol Actuators in 2019. The region’s consistent focus on cost-effective and innovative procedures adopted in the industry is driving the market. The European region held approximately 38.0% of the market, followed by the Asia Pacific, which contains around 22.0% market in the year 2019.
Key participants include Lindal Group, Aptar Group, Coster Group, Mitani Valve Co. Ltd., Summit Packaging Systems, Presspart Manufacturing Ltd., Precision Valve Corporation, E C Pack Industrial Ltd., Ultramotive Corporation, and Newman-Green Inc., among others.
BUY NOW (Customized Report Delivered as per Your Specific Requirement)@ https://www.reportsanddata.com/checkout-form/3643
Segments Covered in the Report:
For the purpose of this report, Reports and Data have segmented into the global Aerosol Actuators market on the basis of Product, Type, application, and region:
Product Outlook (Volume, Kilo Tons; 2017-2027) (Revenue, USD Billion; 2017-2027)
Type Outlook (Volume, Kilo Tons; 2017-2027) (Revenue, USD Billion; 2017-2027)
Aluminum Aerosol Actuators
Application Outlook (Volume, Kilo Tons; 2017-2027) (Revenue, USD Billion; 2017-2027)
Automotive & Industrial
To identify the key trends in the industry, click on the link below: https://www.reportsanddata.com/report-detail/aerosol-actuators-market
Regional Outlook (Volume, Kilo Tons; 2017-2027) (Revenue, USD Billion; 2017-2027)
Rest of Europe
Rest of APAC
Rest of MEA
Rest of LATAM
Take a Look at our Related Reports:
High-Temperature Coatings Market: High-Temperature Coatings Market is forecasted to grow at a rate of 3.9% in terms of value, from USD 3.84 billion in 2019 to reach USD 5.24 billion by 2027. Over the coming years, the market is expected to witness moderate growth due to increased product demand across various applications, such as cooking and bakeware, building and construction, and metal processing.
Coating Equipment market: Coating Equipment market is forecasted to grow at a rate of 6.2% from USD 16.10 billion in 2019 to USD 25.25 billion in 2027. Rising demand for the product from different industries, including automotive, aerospace, and construction is projected to provide a definite room for significant growth in the coming years.
High Performance Coatings Market: High Performance Coatings Market is forecasted to grow at a rate of 4.9% from USD 89.40 billion in 2019 to USD 131.17 Billion in 2027. The growth of the market is mainly associated with the rising demand for industrialization in emerging economies and the rising need to protect products, which are expected to accelerate the market growth globally.
Pigment Dispersion market: Pigment Dispersion market is forecasted to grow at a rate of 5.7% from USD 39.60 billion in 2019 to USD 59.89 billion in 2027. The dispersion of pigments is a process used to transfer color to different substrates in the automotive, manufacturing, and packaging industries.
Powder Coating Equipment market: Powder Coating Equipment market is forecasted to grow at a rate of 7.4% from USD 1.40 billion in 2019 to USD 2.40 billion in 2027. Powder coating equipment is expected to see considerable demand as it offers excellent storage performance, improves flexibility, ease of use, and provides high quality.
Thermal Insulation Coating market: Thermal Insulation Coating market is forecasted to grow at a rate of 6.8% from USD 8.03 billion in 2019 to USD 13.12 billion in 2027. Recent trends in the industrial and automobile industries are expected to fuel demand in specific market segments for heat barrier coats.
About Reports and Data
Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target and analyze consumer behavior shifts across demographics, across industries and help client’s make a smarter business decision. We offer market intelligence studies ensuring relevant and fact-based research across a multiple industries including Healthcare, Technology, Chemicals, Power, and Energy. We consistently update our research offerings to ensure our clients are aware about the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise.
Head of Business Development
Reports And Data | Web: www.reportsanddata.com
Direct Line: +1-212-710-1370
CONTACT: Contact Us: John Watson Head of Business Development Reports And Data | Web: www.reportsanddata.com Direct Line: +1-212-710-1370 E-mail: firstname.lastname@example.org LinkdIn | Twitter | Blogs
Author: Reports and Data
Coronavirus response | State drops Carle lab for tests done at Market Place Mall
URBANA — The coronavirus tests being done at the state’s drive-thru site at Market Place Mall are no longer going to Carle’s in-house lab for results.
The Carle health system ramped up its lab capacity late in the summer, from 2,000 to 3,000 tests a day, to keep up with demand.
But as of Sept. 23, the state drive-thru testing site at the mall stopped sending its specimens to Carle and began sending them to a lab in Pekin, according to Illinois Department of Public Health spokeswoman Melaney Arnold.
“We needed to work with laboratories that are able to bill insurance companies,” she said.
Carle spokeswoman Carolyn Gordon said Carle bills insurance for coronavirus testing deemed medically necessary, as stipulated in a federal relief bill passed in March.
“IDPH indicated to us that its desire was to centralize testing to a single lab,” Gordon said. “Billing insurance was not part of that discussion.”
The Carle lab is currently handling 1,200 to 1,800 tests a day, according to Kayla Banks, Carle’s vice president of quality and infection prevention.
“We’re able to do around 3,000 tests a day, so we do have some unused capacity,” she said.
That 3,000-per-day figure is how many tests the Carle lab can process in a day and still deliver results in 24 to 48 hours, Banks said.
Champaign-Urbana Public Health District Administrator Julie Pryde said her agency wasn’t consulted about the change from the Carle lab to the one in Pekin.
“That was something the state did,” she said.
Still, Pryde said, the turnaround time for results for the 700-800 daily tests being done at the Market Place drive-thru site and sent to Pekin has been averaging about 48 hours, though people are being told it can take longer.
Pryde said she’d like to see the excess capacity at Carle’s testing lab used, because she wants to see the level of testing in the state increase.
“Like I explained to the state, Carle expanded their lab to accommodate all this extra testing, and it’s not being taken advantage of,” she said.
Some excess capacity for the Carle lab isn’t necessarily bad heading into the flu season, Banks said.
Carle is anticipating an uptick in demand for coronavirus testing as flu season arrives, because it’s going to be virtually impossible for sick patients to distinguish on their own what’s causing their symptoms, Banks said.
Carle is planning for its own sites to begin testing symptomatic patients who are coming for coronavirus tests for both that and the flu starting next month, she said.
Carle plans to continue its own coronavirus testing outdoors through the winter, with the addition of a warming station for employees and portable heating, Banks said.
There may be increased instances when the testing sites have to close for inclement weather, she said.
Author: DEBRA PRESSEY email@example.com
ON THE MARKET: Designer features make this Jonesboro home near Lake Jodeco stand out
This 4 bedroom, 3 bathroom Jonesboro home is in walking distance of Lake Jodeco.
Some of the highlights of this home includes designer fixtures and finishes, freestanding European Bathtub, and a home spa.
The kitchen is populated with KitchenAid stainless steel appliances, hardwood flooring, and trendy porcelain tile in wet areas.
The walkout basement includes an area for entertaining with wine and beverage coolers, fireplace, great room, studio, a 2nd master bedroom with spacious bathroom, for your overnight guests.
Outside you will find the 4-car garage has plenty of room for the family’s transportation needs.
Swipe through the photos or a tour of this beautiful home.
The property is listed for $424,900 and is located at:
9243 Floyd Rd, Jonesboro, GA 30236
– Information courtesy Zillow.com
This 5 bedroom, 5 bathroom Craftsman-style, ranch home sits on Lake Spivey in Jonesboro.
This 5 bedroom, 4 bathroom luxury waterfront home on beautiful Lake Spivey hasn’t been on th…
This 5 bedroom home located in the heart of Lake Spivey Country Club, an 18-hole golf course…
The increasing wealth Gap between the Billionaires and the homeless, the decreasing middle class, and the declining jobs as the top 1% continu…
Oman wades back into global debt market with $2bn bond sale
Oman moved ahead with its borrowing plan just days after S&;P cut its debt rating to B+, four rungs below investment grade.
Oman waded back into the international debt market after more than a year with a $2 billion bond sale after raising the possibility of assistance from its Gulf neighbors.
The sultanate dropped plans to place a bond with a three-year maturity on Wednesday and is selling $1.25 billion of seven-year notes and $750 million of 12-year securities, according to a person familiar with the deal. It’s in preliminary talks to win support from some states in the region, according to its bond prospectus.
Derivatives traders have pared back wagers for a devaluation of the Omani rial on anticipation that the wealthier Gulf states will come to the country’s rescue – as they did for Bahrain two years ago – if its peg to the dollar comes under threat.
Oman has lagged most peers in implementing fiscal reforms despite dwindling reserves and a budget deficit S&P Global Ratings estimates could reach 18% of gross domestic product this year. The government was facing increasing pressure to tap global debt markets as a widening fiscal shortfall leaves the sovereign underfunded by about 1.3 billion rials ($3.4 billion) to 1.4 billion rials, according to Morgan Stanley.
“Given the weakness in external balances, the buyers will likely be those who ascribe a greater probability of support if it comes down to it, in the Bahrain-type of model,” said Todd Schubert, head of fixed-income research at Bank of Singapore.
The sultanate’s long-standing role as a mediator on regional and international issues, including with Iran, and its geographical position on one of the world’s busiest shipping lanes, make its stability important to Gulf states and international allies like the U.S.
At the same time, Oman’s resistance to taking sides in regional disputes and adopting Saudi Arabia’s foreign policies could complicate efforts to secure help from its neighbors.
Oman forged ahead with its borrowing plan just days after S&P cut its debt rating to B+, four rungs below investment grade. While the government said it wants to introduce a delayed 5% value-added tax in April, S&P said fiscal austerity measures will probably only be rolled out gradually.
Under a medium-term fiscal program created to strengthen public finances, Oman also plans to introduce income tax on high earners, according to the bond prospectus.
“The new deal comes at a tricky time for the country,” said Abdul Kadir Hussain, the head of fixed-income asset management at Arqaam Capital in Dubai. “The market knows they need the funding. It’s relatively close to year-end, so investors generally tend to get a bit defensive around this time of the year anyway.”
Underscoring the hurdles, Turkey’s sovereign wealth fund and Ukraine’s state-controlled oil and gas company Naftogaz Ukrainy pulled debt offerings on Tuesday.
Oman’s government expects to price the shorter notes at a yield of 6.75%, down from initial guidance in the 7% area. It’s aiming to price the 12-year securities at 7.375%, down from about 7.625%, the person familiar with the matter said, asking not to be identified because they’re not authorized to speak about it.
Oman’s bonds are the worst performers in the region this year, and, until now, the country had stayed out of the market after raising $3 billion last year.
“This will significantly reduce the pressure to raise domestic debt or draw down their reserves,” said Monica Malik, chief economist at Abu Dhabi Commercial Bank. “The funding requirement will remain high going forward, so continued access to the international debt market is important.”
(Updates with bond sale amount from first paragraph)
-With assistance from Lyubov Pronina, Archana Narayanan and Finbarr Flynn.
Author: By Netty Ismail and Abeer Abu OmarBloomberg
The Crypto Market Feeling Bullish, With Ethereum Climbing 15% Higher – Forex News by FX Leaders
ETHEREUM crashed lower in March, as most major cryptoocurrencies during the initial coronavirus panic, falling from $250 to $90. But, the decline ended and since the middle of that month, Ethereum has been quite bullish, gaining more than 4 times in value.
Until August, the 20 SMA (grey) and the 50 SMA (yellow) were providing support. That lasted until August when the price surged higher. Ethereum surged to $490 on September 1, but then retreated back down, as the USD started to gain some strength, after declining for months.
Although, the decline in ETH/USD stopped above $300, where it seems to have formed a base, after that area rejected the price for a second time in late September, helped by the 100 SMA (green) which provided support. The price broke above the 50 SMA (yellow) on the daily chart and this moving average which provided resistance in September, turned into support now.
In the last two days, the crypto market has moved higher again, as the USD turned bearish, and Ethereum bounced off the 50 SMA. Paypal aid to be adopting cryptocurrencies soon, which is another reason for the surge this week. So, the momentum is bullish for Ethereum and we will try to go long if we see the price retrace down to the 50 SMA and the 50 SMA holds. Until then, we will follow the price action.